Literature DB >> 31999327

A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia.

Max Jan1,2, Daniel E Grinshpun2,3, Julian A Villalba1, Paola Dal Cin4,5, David B Sykes4,6, A John Iafrate1,4, Benjamin L Ebert2,3,4,7, Gabriela S Hobbs4,8, Valentina Nardi1,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31999327      PMCID： PMC7013269          DOI： 10.1182/bloodadvances.2019001182

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  14 in total

1.  Identification of the SH3 domain of GAP as an essential sequence for Ras-GAP-mediated signaling.

Authors:  M Duchesne; F Schweighoffer; F Parker; F Clerc; Y Frobert; M N Thang; B Tocqué
Journal:  Science       Date:  1993-01-22       Impact factor: 47.728

2.  Anchored multiplex PCR for targeted next-generation sequencing.

Authors:  Zongli Zheng; Matthew Liebers; Boryana Zhelyazkova; Yi Cao; Divya Panditi; Kerry D Lynch; Juxiang Chen; Hayley E Robinson; Hyo Sup Shim; Juliann Chmielecki; William Pao; Jeffrey A Engelman; A John Iafrate; Long Phi Le
Journal:  Nat Med       Date:  2014-11-10       Impact factor: 53.440

Review 3.  Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta.

Authors:  E Joanna Steer; Nicholas C P Cross
Journal:  Acta Haematol       Date:  2002       Impact factor: 2.195

Review 4.  Myeloid neoplasms with eosinophilia.

Authors:  Andreas Reiter; Jason Gotlib
Journal:  Blood       Date:  2016-12-27       Impact factor: 22.113

5.  Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.

Authors:  Mohamad Jawhar; Nicole Naumann; Juliana Schwaab; Herrad Baurmann; Jochen Casper; Tu-Anh Dang; Lutz Dietze; Konstanze Döhner; Annette Hänel; Bernd Lathan; Hartmut Link; Sina Lotfi; Ole Maywald; Stephan Mielke; Lothar Müller; Uwe Platzbecker; Otto Prümmer; Henrike Thomssen; Karin Töpelt; Jens Panse; Tom Vieler; Wolf-Karsten Hofmann; Torsten Haferlach; Claudia Haferlach; Alice Fabarius; Andreas Hochhaus; Nicholas C P Cross; Andreas Reiter; Georgia Metzgeroth
Journal:  Ann Hematol       Date:  2017-07-19       Impact factor: 3.673

6.  Abnormalities of chromosome 12p13 and malignant proliferation of eosinophils: a nonrandom association.

Authors:  P Keene; B Mendelow; M R Pinto; W Bezwoda; L MacDougall; G Falkson; P Ruff; R Bernstein
Journal:  Br J Haematol       Date:  1987-09       Impact factor: 6.998

7.  Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.

Authors:  Jane F Apperley; Martine Gardembas; Junia V Melo; Robin Russell-Jones; Barbara J Bain; E Joanna Baxter; Andrew Chase; Judith M Chessells; Marie Colombat; Claire E Dearden; Sasa Dimitrijevic; François-X Mahon; David Marin; Zariana Nikolova; Eduardo Olavarria; Sandra Silberman; Beate Schultheis; Nicholas C P Cross; John M Goldman
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

8.  Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China.

Authors:  Shi-Qiang Qu; Tie-Jun Qin; Ze-Feng Xu; Yue Zhang; Xiao-Fei Ai; Bing Li; Hong-Li Zhang; Li-Wei Fang; Li-Juan Pan; Nai-Bo Hu; Zhi-Jian Xiao
Journal:  Oncotarget       Date:  2016-05-31

9.  G3BP1 promotes tumor progression and metastasis through IL-6/G3BP1/STAT3 signaling axis in renal cell carcinomas.

Authors:  Yong Wang; Donghe Fu; Yajing Chen; Jing Su; Yiting Wang; Xin Li; Wei Zhai; Yuanjie Niu; Dan Yue; Hua Geng
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

10.  Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.

Authors:  Qingsong Gao; Wen-Wei Liang; Steven M Foltz; Gnanavel Mutharasu; Reyka G Jayasinghe; Song Cao; Wen-Wei Liao; Sheila M Reynolds; Matthew A Wyczalkowski; Lijun Yao; Lihua Yu; Sam Q Sun; Ken Chen; Alexander J Lazar; Ryan C Fields; Michael C Wendl; Brian A Van Tine; Ravi Vij; Feng Chen; Matti Nykter; Ilya Shmulevich; Li Ding
Journal:  Cell Rep       Date:  2018-04-03       Impact factor: 9.423
View more
  3 in total

Review 1.  Updates on eosinophilic disorders.

Authors:  Alexandar Tzankov; Kaaren K Reichard; Robert P Hasserjian; Daniel A Arber; Attilio Orazi; Sa A Wang
Journal:  Virchows Arch       Date:  2022-09-07       Impact factor: 4.535

2.  Performances of Targeted RNA Sequencing for the Analysis of Fusion Transcripts, Gene Mutation, and Expression in Hematological Malignancies.

Authors:  Sandrine Hayette; Béatrice Grange; Maxime Vallee; Claire Bardel; Sarah Huet; Isabelle Mosnier; Kaddour Chabane; Thomas Simonet; Marie Balsat; Maël Heiblig; Isabelle Tigaud; Franck E Nicolini; Sylvain Mareschal; Gilles Salles; Pierre Sujobert
Journal:  Hemasphere       Date:  2021-01-27

3.  G3BP2-KIT drives leukemia amenable to kinase inhibition in Ph-like ALL.

Authors:  Ilaria Iacobucci; Reiji Fukano; Jake D Friske; Chunxu Qu; Laura J Janke; Yaqi Zhao; Pradyuamna Baviskar; Emily A Backhaus; Peter Chockley; Aman Seth; A Douglas Laird; Anjali S Advani; Charles G Mullighan
Journal:  Blood Adv       Date:  2022-06-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.